PharmaKure granted MHRA Clinical Trial Authorisation (CTA) for PK051 for the treatment of mild cognitive impairment due to Alzheimer's Disease

Clinical Trial Authorisation application granted for combined drug PK051 targeting amyloid deposits associated with Alzheimer’s Disease.

Related Keywords

United Kingdom ,Bob Smith ,Farid Khan ,Healthcare Regulatory Agency ,From Pharmakurejan ,United Kingdom Medicines ,Clinical Trial Authorisation ,Chief Clinical Director ,Clinical Trial ,Flood ,Blood Test ,Healthcare ,Neurodegenerative Diseases ,